Aridis Pharmaceuticals Inc’s Quiet Period Will End on September 24th

Aridis Pharmaceuticals’ (NASDAQ:ARDS) quiet period is set to end on Monday, September 24th.

Aridis Pharmaceuticals had issued 2,000,000 shares in its public offering on August 14th. The total size of the offering was $26,000,000 based on an initial share price of $13.00.

During the company’s quiet period, insiders and any underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

ARDS has been the subject of several recent research reports.

Northland Securities assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They issued an “outperform” rating for the company.

Laidlaw assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set a “buy” rating and a $23.00 price objective for the company.

Cantor Fitzgerald assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set an “overweight” rating for the company.

Finally, Northcoast Research assumed coverage on shares of Aridis Pharmaceuticals in a research note on Monday, September 10th. They set an “outperform” rating and a $40.00 price objective for the company.

LEAVE REPLY

Your email address will not be published. Required fields are marked *